Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...

Below, I'll break down what's going on at Viking and explain how the company may emerge as a competitive force in the weight ...

The United Kingdom will study whether the use of weight loss drugs could get people back to work. UK Health Minister Wes ...

Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...

The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...

Despite the success of its new weight loss drug Zepbound, Lilly's recent earnings failed to meet expectations.

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...